Their RSV injection killed more babies in the experimental group than the control.
A preprint study published June 11 indicated that infants who partook in a respiratory syncytial virus (RSV) injection campaign suffered from antibody dependent enhancement (ADE) and some even died.
Full access to the study can be had by downloading the PDF.
ADE is where the body’s immune response worsens the effects of the viral infection.
“Antiviral antibodies constitute an important component of the host immune response against viral infections and serve to neutralize and reduce infectivity of the virus. However, these antibodies, intended to protect the host, may sometimes prove beneficial to the virus, by facilitating viral entry and replication in the target cell,” a paper on ADE said in the ‘Abstract’ section.
The injection the infants received in the study was Beyfortus, also known as Nirsevimab, which is a monoclonal antibody for RSV.
Infowars previously reported on VAERS reports documenting babies dying after receiving the injection along with an RSV vaccine meant for the elderly*.
“In France, there is a significant signal of an increase in newborn deaths between 2 and 6 days of age during the 2023-2024 immunization campaign. This signal could be attributable to ADE (antibody-dependent-enhancement). ADE has been observed with RSV F-protein antibodies in inactivated vaccine trials,” the study said in the ‘Abstract’ section.
Not only was the RSV injection dangerous to the health of the babies, it also was not seen to be effective either.
“Neither clinical trials nor observational studies point to a reduction in all-cause hospitalizations in the immunized age group in this same season compared with previous seasons,” the study said in the ‘Abstract’ section.
Besides ADE and hospitalizations, some infants in the experiment had the misfortune of dying. While there were deaths in both the injected and non-injected groups, the injected infants died at a greater rate.
“The FDA notes an imbalance of deaths in favor of the treated group: 12 deaths in the 3,710 treated participants (0.32%) versus 4 in the 1,797 control participants (0.22%), taking into account one death in the placebo group 6 days after the end of the study and without specifying deaths in the treated groups after the end of the study [93]. In the studies listed by the EMA, 8 deaths were recorded (with the same percentage – 0.3% – in the treated and placebo groups). The Domachowske study [89] (which was published as a correspondence, i.e. not peer-reviewed) concerns premature babies and newborns suffering from heart or lung disease, and compares the effect of the monoclonal antibody previously used (Synagis, palivizumab) with Beyfortus (nirsevimab),” the study said in the section ‘6.1.3. Deaths in Trials’. “It provides a full description of the deaths observed: of the 6 deaths listed, 5 were related to pneumonia or bronchiolitis not attributed to treatment (5 babies who died were treated with Beyfortus (5/614 = 0.81%) and 1 (1/304 = 0.32%) with Synagis). Despite the low number of deaths, there was an imbalance against nirsevimab. 6.86% of treated children (63/918) were withdrawn from the study.”
Infants in other RSV experiments died as well and others had to be hospitalized once exposed to RSV in real life, post-vaccination.
“In 2021, Polack [54] re-examined the case of two young children who died of RSV disease after being vaccinated with an inactivated vaccine in trial (80% of children vaccinated and subsequently infected with RSV had to be hospitalized),” the study said in section ‘4.5. The Same Mechanisms are at Play for ADE in RSV Infection’.
Interestingly, ADE has been documented to stem from the Covid vaccine and can cause RSV infection.
“ADE can increase the severity of multiple viral infections, including other respiratory viruses such as respiratory syncytial virus (RSV),” a study in Nature said in the ‘Main’ section.
One of the study authors spoke with The Defender regarding the study.
“She also said that observational studies, like the one published today in the New England Journal of Medicine on the French campaign consistently exclude babies hospitalized for RSV illness within seven days of their shot,” an article by Brenda Baletti, Ph.D. in The Defender said. “But those illnesses may be due to ADE from the shot. So while that study reported similar efficacy findings to Banoun’s, it doesn’t account for some potential serious safety issues. However, there was no reduction in the overall number of infants admitted to the hospitals and clinical trials similarly showed no reduction in hospitalizations.”
